ResearcherNational and Kapodistrian University of AthensActive in the last 2 years

Chrysovalantou Mihailidou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7907-7243; OpenAlex author ID A5074782060. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Retraction: Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. Co-author DOI 10.18632/oncotarget.28601 ↗
Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. Co-author DOI 10.18632/oncotarget.23164 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Pavlos Papakotoulas · 2 shared papers, 2018–2024 · strength 0.43
- Paper Retraction: Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. DOI 10.18632/oncotarget.28601 ↗
- Paper Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. DOI 10.18632/oncotarget.23164 ↗
Michalis V. Karamouzis · 2 shared papers, 2018–2024 · strength 0.43
- Paper Retraction: Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. DOI 10.18632/oncotarget.28601 ↗
- Paper Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. DOI 10.18632/oncotarget.23164 ↗
Athanasios G. Papavassiliou · 2 shared papers, 2018–2024 · strength 0.43
- Paper Retraction: Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. DOI 10.18632/oncotarget.28601 ↗
- Paper Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. DOI 10.18632/oncotarget.23164 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.